- Meeting abstract
- Open Access
Metabolic manipulation in Dilated Cardiomyopathy: assessing the role of trimetazidine
Journal of Cardiothoracic Surgery volume 10, Article number: A7 (2015)
Altered substrate metabolism plays an important role in pathophysiology of heart failure (HF). Optimization of myocardial energy metabolism with metabolic modulators like trimetazidine (TMZ) allows more efficacious energy production.
Although TMZ has been studied extensively in patients with ischemic HF, more data are needed on its role in dilated cardiomyopathy (DCM).
100 patients of DCM (mean age 47.7 yrs, NYHA class 2.17, LVEF 27.3%) were randomized to TMZ (20 mg tid, n = 50) vs conventional therapy (n = 50). Functional status, BNP & echocardiographic parameters were assessed at 3-6 months.
Baseline characteristics were comparable among the two groups. At three months, patients on TMZ had significant improvement in mean NYHA class (2.25 vs 1.85, p = .001), 6 min walk test (349.7vs 402 m, p = 0.001), LVD-36 score (25.5 vs 21, p = .001) and fall in BNP (744.7 vs 248.3 pg/ml, p = .001). This was accompanied by significant improvement in indexed LV end-systolic (LVESV, 87.1 ± 27.5 vs 78.5 ± 24.9 ml/m2, p = 0.0001) and LV end-diastolic volumes (LVEDV, 117.6 ± 29.3 vs 110.9 ± 27.4 ml/m2, p = 0.0001) and LVEF (27vs30.9%, p = .0001) along with reduction in LV wall stress (90.2 ± 18.9 vs 71.1 ± 13.2 dyn/cm2, p = 0.0001). Other echocardiographic parameters also improved after three 3 month of TMZ (E/A ratio, E/A VTI, Myocardial performance index) and TDI parameters (E/e'septal, and E/e' lateral). Patients not on TMZ had no significant change in NYHA Class, LVD-36 scores, LV volumes or LVEF at 3 months although BNP levels & LV wall stress reduced, albeit to a lesser extent than TMZ. Patients on TMZ had further improvement in NYHA Class, 6 min walk test, BNP levels & all echocardiographic parameters at 6 months.
Metabolic modulators like trimetazidine have a potential role to play in altering LV remodelling and improving LV function in DCM. In this study, benefit was noted by 3 months with further improvement at 6 months.
About this article
Cite this article
Kapoor, A., Jatain, S., Agarwal, S.K. et al. Metabolic manipulation in Dilated Cardiomyopathy: assessing the role of trimetazidine. J Cardiothorac Surg 10, A7 (2015). https://doi.org/10.1186/1749-8090-10-S1-A7
- Dilate Cardiomyopathy
- NYHA Class
- Echocardiographic Parameter
- Myocardial Performance Index